Craft

Sunesis Pharmaceuticals

Revenue

$120 K

FY, 2020

Sunesis Pharmaceuticals Summary

Company Summary

Overview
Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers. It develops QINPREZO (vosaroxin), an anti-cancer quinolone derivative, or AQD — a class of compounds. The company conducts research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology.
Type
Subsidiary
Status
Active
Founded
1987
HQ
South San Francisco, CA, US | view all locations
Website
http://www.sunesis.com/
Cybersecurity rating
Sectors

Key People

  • Deepali Suri

    Deepali Suri, Vice President, Head of Clinical Operations

  • Parvinder S. Hyare

    Parvinder S. Hyare, Head of Global Oncology Operations

  • James W. Young

    James W. Young, Chairman

    • Dayton Misfeldt

    LocationsView all

    1 location detected

    • South San Francisco, CA HQ

      United States

      395 Oyster Point Blvd

    Sunesis Pharmaceuticals Financials

    Summary Financials

    Net income (Q3, 2022)
    ($17.7M)
    EBIT (Q3, 2022)
    ($18.1M)

    Footer menu